• Samsung C&T corrected Samsung Biologics' planned PolyPeptide acquisition settlement date to Dec. 31, 2026, from Nov. 30, 2026.
• The planned cash acquisition covers 33,016,411 shares for KRW 2.71 trillion, aimed at strengthening its peptide CDMO business.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Samsung C&T Corporation published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261016800879), on October 16, 2026, and is solely responsible for the information contained therein.